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MaAtrial ﬁbrillation (AF) is associated with structural, electrical, and contractile remodeling of the atria. Development and
progression of atrial ﬁbrosis is the hallmark of structural remodeling in AF and is considered the substrate for AF
perpetuation. In contrast, experimental and clinical data on the effect of ventricular ﬁbrotic processes in the pathogenesis
of AF and its complications are controversial. Ventricular ﬁbrosis seems to contribute to abnormalities in cardiac relax-
ation and contractility and to the development of heart failure, a common ﬁnding in AF. Given that AF and heart failure
frequently coexist and that both conditions affect patient prognosis, a better understanding of the mutual effect of
ﬁbrosis in AF and heart failure is of particular interest. In this review paper, we provide an overview of the general
mechanisms of cardiac ﬁbrosis in AF, differences between ﬁbrotic processes in atria and ventricles, and the clinical and
prognostic signiﬁcance of cardiac ﬁbrosis in AF. (J Am Coll Cardiol 2015;66:943–59) © 2015 by the American College of
Cardiology Foundation.T he mechanisms of atrial ﬁbrillation (AF) arecomplex and associated with structural andelectrical remodeling in the atria and ventric-
ular myocardium. The key electrophysiological mech-
anisms of AF include: 1) focal ﬁring due to triggered
activity (early and delayed afterdepolarizations);
2) multiple re-entries due to shortening of the action
potential; and 3) heterogeneity of impulse conduc-
tion caused by atrial ﬁbrosis. Development and
progression of atrial ﬁbrosis are the hallmark of struc-
tural remodeling in AF and are considered to be the
substrate for AF perpetuation. Advanced atrial
ﬁbrosis is associated with more frequent paroxysms
of AF, transformation of the arrhythmia into a perma-
nent type, and reduced effectiveness of antiar-
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
CHADS2 = congestive heart
failure, hypertension, age
‡75 years, diabetes mellitus,
and stroke/transient ischemic
attack
CMR = cardiac magnetic
resonance
CTGF = connective tissue
growth factor
DE-CMR = delayed gadolinium
enhancement cardiac magnetic
resonance
ECM = extracellular matrix
HF = heart failure
miR = microribonucleic acid
MMP = matrix
metalloproteinase
NADPH = nicotinamide
adenine dinucleotide
phosphate
PDGF = platelet-derived
growth factor
TGF-b1 = transforming growth
factor beta-1
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ences between ﬁbrotic processes in the atria
and ventricles, and the clinical and prog-
nostic effect of cardiac ﬁbrosis in AF.
MECHANISMS OF CARDIAC FIBROSIS
Progressive accumulation of ﬁbrotic tissue in
myocardium is 1 of the major components of
cardiac remodeling. Formation and redistri-
bution of connective tissue ﬁbers modulate
myocardial geometry to adapt to new con-
ditions of (patho)physiological functioning
and to prevent or minimize the effects of
new mechanical, chemical, and electrical
stimuli. This adaptation process involves
both the cellular components of the myo-
cardium and the extracellular matrix (ECM),
an acellular component of the heart, con-
taining a variety of ﬁbers, with collagen
predominant (4).
Excessive ECM production in adults is
commonly associated with the pathogenesis
of cardiovascular diseases, resulting in ab-
normalities of cardiac contraction and relax-
ation, and thus inevitably leading to HF (5).Although collagen deposition in the healthy heart is
restricted to maintenance of heart architecture, dur-
ing progression of various cardiac disorders, the
collagen network undergoes quantitative and quali-
tative changes leading to excessive accumulation of
collagen, either in regions of cardiomyocyte loss (e.g.,
in myocardial infarction, reparative ﬁbrosis) or
diffusely, in areas of the myocardium not involved in
the focal injury (e.g., in dilated cardiomyopathy,
reactive ﬁbrosis) (4,5).
CARDIAC FIBROBLASTS AND MYOFIBROBLASTS. Both
cellular and extracellular components take part in the
remodeling process. Cardiac ﬁbroblasts play a pivotal
role in formation of the ECM. They are numerous
within the myocardium and can account for up to
60% of cells in cardiac muscle (6). Thus, cardiac ﬁ-
broblasts outnumber even cardiomyocytes, although
the latter cells largely determine total myocardial
mass.
The population of cardiac ﬁbroblasts in healthy
adult hearts is maintained at a relatively low
level and is predominantly composed of resident
ﬁbroblasts and cells undergoing an epithelial-to-
mesenchymal transition. In pathological conditions,
ﬁbroblasts dramatically increase in number via dif-
ferentiation from several cell lineages, including
monocytes, endothelial cells, bone marrow–circu-
lating progenitor cells, and pericytes (7–9).The physiological functions of ﬁbroblasts extend
beyond metabolism of the ECM. Tight connections
between the ﬁbroblasts, ﬁbers of the ECM, and other
cellular components form a multidimensional
network that acts as an integral sensor of dynamic
changes in the various mechanical, chemical, and
electrical stimuli in the myocardium. In response to
these stimuli, this complex system adjusts ECM
turnover and regulates cardiomyocyte hypertrophy
and, to a smaller extent, cardiomyocyte proliferation;
it also triggers activation of ﬁbrotic and inﬂammatory
pathways. Of note, cardiac ﬁbroblasts exhibit various
phenotypes depending on the surrounding microen-
vironment (10).
Cardiac ﬁbroblasts might also contribute to
electrical remodeling in AF due to their different
electrophysiological properties compared with the
surrounding cardiomyocytes. Fibroblasts are essen-
tially nonexcitable cells but can transfer currents
between cardiomyocytes via connexins in vitro. This
action may result in heterogeneity of current con-
duction, shortening of action potentials, depolariza-
tion of resting cardiomyocytes, and induction of
spontaneous phase 4 depolarization (11). Conse-
quently, ﬁbroblasts might be directly involved in the
occurrence and perpetuation of re-entry, although
further research is needed to provide in vivo evidence
for this claim. Interestingly, computer modeling
found proliferation of myoﬁbroblasts in AF and their
electrical interaction with cardiomyocytes to be suf-
ﬁcient for re-entry formation, even in the absence of
ﬁbrosis (12).
Myoﬁbroblasts are cells that play a particularly
signiﬁcant role in cardiac ﬁbrosis. They are derived
from cardiac ﬁbroblasts but have an w2-fold higher
capacity to synthesize collagen. Compared with car-
diac ﬁbroblasts, myoﬁbroblasts do not appear in
healthy myocardium, are more responsive to proin-
ﬂammatory and proﬁbrotic stimuli, and are capable
of synthesizing a large variety of cytokines and
chemokines (13). Importantly, myoﬁbroblasts contain
alpha-smooth muscle actin and adhesion complexes
(ﬁbronexus). The latter binds myoﬁbroblast internal
microﬁlaments to ECM proteins that help to provide
contractile force to the surrounding ECM.
A range of growth factors, cytokines, and hor-
mones, as well as mechanical stretch and hypoxia,
regulate ECM turnover and cardiac ﬁbroblast activity.
These factors determine ﬁbroblast gene expression,
their differentiation, and the level of collagen
synthesis.
TRANSFORMINGGROWTH FACTOR-b1 SIGNALING. Among
the numerous regulatory factors, angiotensin II and
transforming growth factor beta-1 (TGF-b1) (Figure 1)
FIGURE 1 Schematic Overview of the TGF-b1–Signaling Pathway in Cardiac Fibrosis
COL1A1¼geneencodingalpha-1typeIcollagen;COL1A2¼geneencodingalpha-2typeIcollagen;
COL3A1¼ gene encoding a1 type III collagen; CTGF¼ connective tissue growth factor; ECM¼
extracellularmatrix; ERK¼ extracellular signal-regulated kinase; JNK¼ c-junN-terminal kinase;
LOX¼ lysyl oxidase; LTBP¼ latent transforming growth factor beta-1 binding protein;MMP¼
matrixmetalloproteinase; p38¼ protein 38 (member of MAPK,mitogen-activated protein
kinases); SAPK¼ stress-activated protein kinase; Smad¼ a transcription factor (as discussed in
Table 1);TAK1¼ transforminggrowth factorbeta-1 activatedkinase 1;TbRI¼ type I transforming
growth factor beta-1 receptor; TbRII¼ type II transforming growth factor beta-1 receptor;
TGF-b1¼ transforminggrowth factorbeta-1;TIMP¼ tissue inhibitorofmatrixmetalloproteinase.
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by cardiac ﬁbroblasts (14,15). TGF-b1 produces its ef-
fects via binding to the dimerized TGF-b1 receptor
(which consists of 2 receptors, TbRI and TbRII) in the
extracellular space. Ligand-receptor binding results
in a cascade of phosphorylation reactions during
which inactive Smad proteins 2, 3, and 4 form the
Smad complex (16).
The Smad complex then translocates to the nuclei
of target cells, where it regulates expression of genes
involved in ﬁbrogenesis (e.g., connective tissue
growth factor [CTGF] and periostin) via appropriate
regulatory regions (17,18). This action results in pro-
duction of the so-called matricellular protein, a
proﬁbrotic protein secreted into the ECM. The
matricellular protein modulates intercellular and
cell–matrix interactions that further stimulate ECM
protein synthesis but are not directly involved in ECM
structure and mechanical organization or differenti-
ation of cardiac ﬁbroblasts into myoﬁbroblasts (19).
TGF-b–activated kinase 1, an alternative to the
Smad pathway for TGF-b1–induced ﬁbrosis, is a
member of the mitogen-activated protein kinase
family (20). Importantly, apart from activation of
ﬁbroblast and collagen synthesis, TGF-b1 can also
induce apoptosis of cardiomyocytes (21).
Of note, angiotensin II is not able to induce cardiac
hypertrophy and ﬁbrosis in the absence of TGF-b1,
but it up-regulates TGF-b1 synthesis, Smad2 phos-
phorylation, and nuclear translocation of the Smad
complex and increases Smad deoxyribonucleic acid—
binding activity. TGF-b1, in turn, can directly stimu-
late expression of angiotensin II type 1 receptor
(22). Angiotensin II also predisposes to ﬁbrosis by
promoting expression of proﬁbrotic factors, such
as endothelin-1. In conjunction with aldosterone,
angiotensin II promotes oxidative stress (i.e., excess
production of reactive oxygen species) and inﬂam-
mation, mainly by activation of nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase (23,24).
MATRIX METALLOPROTEINASES AND TISSUE INHIBITORS
OF MATRIX METALLOPROTEINASES. The remodeling
and maintenance process of the extracellular space
includes not only synthesis but also coordinated
degradation of the ECM proteins. Matrix metal-
loproteinases (MMPs) and their tissue inhibitors,
synthesized by cardiomyocytes and cardiac ﬁbro-
blasts, are intimately involved in the maintenance of
ECM homeostasis (25). Indeed, MMP expression in-
creases in a time-dependent manner with left ven-
tricular dysfunction and dilation (26). Overexpression
of MMP1 has been shown to cause compensatory
hypertrophy and increased collagen concentration
within the myocardium. In contrast, targeted deletion
FIGURE 2 Involvem
Tissue injury
(AF, HF)
AF ¼ atrial ﬁbrillatio
RAAS ¼ renin-angiot
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remodeling (27). Not surprisingly, MMP activity in-
creases in line with TGF-b1 expression within the
myocardium and correlates with the level of inﬂam-
mation and oxidative stress (28).
Furthermore, collagen and matrix fragments pro-
duced by the action of MMP1 themselves form
bioactive molecules, so-called matrikines, and release
ECM-embedded proinﬂammatory and proﬁbrotic
factors. They promote ﬁbroblast activation and tran-
sition to a myoﬁbroblast phenotype, and they effec-
tively stimulate connective tissue synthesis by
serving as ligands of leukocyte integrins and other
cell-activating receptors (25,29). The latter explains
the progression of ﬁbrosis when MMP activity is high,
despite the primary MMP function being directed
toward matrix degradation. MMP activity is regulated
via tissue inhibitors of MMPs and reversion-inducing
cysteine-rich protein with Kazal motifs, over-
expression of which has been found to blunt angio-
tensin II–induced MMP activation and cardiac
ﬁbroblast migration (30).
REGULATORY ROLE OF MICRORIBONUCLEIC ACIDS.
Nuclear microribonucleic acids (miRs) play important
regulatory roles in cardiac remodeling (31). They
are referred to as endogenous, single-stranded, short
(w22 nucleotides), noncoding ribonucleic acids.
miRs degrade or inhibit the translation of their
target messenger ribonucleic acids at the post-
transcriptional level, thus regulating gene expres-
sion (32).ent of Inﬂammation Pathways in Cardiac Fibrosis
Activated
inflammatory
cells
(neutrophils,
lymphocytes,
monocytes,
resident
macrophages,
mast cells,
platelets)
Low grade
inflammatory
response
IL-1, IL-6,
TNFα, MPO,
PDGF
Transcriptio
factors (e.g
NF-kB)
n; HF ¼ heart failure; IL ¼ interleukin; MPO ¼ myeloperoxidase; NF-kB ¼ nu
ensin-aldosterone system; TGF-b1 ¼ transforming growth factor b1; TNF ¼ tSeveral miRs are involved in ﬁbrogenesis. miR-133
and miR-30 regulate cardiac ﬁbrosis by repressing
CTGF expression. They were found to be down-
regulated in left ventricular hypertrophy associated
with increased CTGF expression (33). miR-133
knockout mice developed advanced ﬁbrosis and HF
with predisposition to sudden death (34). In contrast,
miR-133 overexpression resulted in decreased
collagen synthesis by ﬁbroblasts, reduced myocardial
ﬁbrosis, and apoptosis (33,35). miR-21 is involved in
up-regulation of 1 of the proﬁbrotic pathways (ERK)
and promotes MMP2 expression (36,37). Interestingly,
it also produces protective effects, including defense
against oxidative stress, inhibition of proapoptotic
factors, and increased expression of antiapoptotic
genes (38). Finally, miR-29 is associated with depo-
sition of collagen types I and III. Up-regulation of
miR-29 leads to down-regulation of these proteins
and vice versa (39).
INFLAMMATION. AF is common in patients with
overt inﬂammatory states of cardiac and noncardiac
location (e.g., myocarditis, pericarditis, pneumonia,
and inﬂammatory bowel disease), but low-grade
subclinical inﬂammation (e.g., in coronary heart
disease) also contributes to pathogenesis of the
arrhythmia (Figure 2) (40). Regardless of whether
AF is a cause or consequence of the inﬂammatory
process, it is related to oxidative stress perpetuated
by myocardial inﬁltration with inﬂammatory cells
(e.g., macrophages), which is accompanied by release
of reactive oxygen species. Inﬂammation is furthernal
.
Gene
expression of
inflammatory
cytokines
Maintenance of
inflammation,
RAAS
activation,
oxidative
stress, TGF-β1
signaling
Apoptosis of
cardiomyocytes,
fibroblast
recruitment,
ECM deposition
clear factor kappa B; PDGF ¼ platelet-derived growth factor;
umor necrosis factor.
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aldosterone system, followed by activation of
NADPH oxidase. These processes consequently
trigger TGF-b1 signaling and structural and electrical
remodeling (41). Various inﬂammatory cytokines and
chemokines, such as interleukin-1 and -6, tumor ne-
crosis factor-alpha, and monocyte chemoattractant
protein 1, are up-regulated in AF and linked to pro-
gression from paroxysmal to chronic AF and AF
recurrence post-cardioversion (40).
Inﬂammation plays a particular role in post-
operative AF (e.g., after coronary artery bypass graft,
valvular replacement surgery) and post–catheter
ablation. In a recent meta-analysis of 925 post-
operative patients, serum C-reactive protein was a
potent predictor of new-onset AF (42). Similarly, a
meta-analysis of 7 studies of post-ablation patients
conﬁrmed the predictive role of C-reactive protein for
AF recurrence (43).
AGING AND CARDIAC FIBROSIS
The prevalence of AF signiﬁcantly increases in the
elderly. Cardiac aging is a complex process, featuring
progressive decline in heart functions and ventricular
and atrial remodeling. This process includes re-
duction in cardiomyocyte numbers, hypertrophy of
the remaining cardiomyocytes, alteration of myoﬁ-
brillar orientation, proliferation of cardiac ﬁbroblasts,
and collagen deposition. Progressive ﬁbrosis is a
hallmark of the aging heart, as conﬁrmed in animal
and human studies showing an increased collagenFIGURE 3 Oxidative Stress in Cardiac Fibrosis
Tissue injury
(AF, HF),
RAAS
activation
NADPH
oxidase,
xanthine
oxidoreductase,
uncoupled
NOS, electron
transport chain
in the mitochondria
Intracellular
accumulation
of ROS
(oxidative
stress)
ERK ¼ extracellular signal-regulated kinase; JNK ¼ c-Jun N-terminal kin
dinucleotide phosphate; NOS ¼ nitric oxide synthase; p38 ¼ protein 38volume fraction in the myocardium and by result of
imaging (44).
Age-related cardiac ﬁbrosis reﬂects multiple pro-
cesses that accompany cardiac senescence, chronic
activation of the renin-angiotensin-aldosterone axis,
excessive beta-adrenergic and endothelin signaling,
activation of the TGF-b1 pathway, disruption of
intracellular calcium homeostasis, cardiomyocyte
apoptosis, recruitment of mononuclear cells and
ﬁbroblast progenitors, and down-regulation of the
mitochondrial nicotinamide adenine dinucleotide–
dependent deacetylase sirtuin-1 (45).
Increased generation of reactive oxygen species
and diminished antioxidant capacity are major con-
tributors to age-related myocardial remodeling
(Figure 3). Oxidative molecules derive from oxidative
phosphorylation processes in mitochondria, increased
NADPH oxidase activity, uncoupled nitric oxide syn-
thase function, lipid oxidation within peroxisomes,
and up-regulation of cyclooxygenases and xanthine
oxidase (46). Chronic oxidative stress leads to the
persistence of low-grade inﬂammation, thus further
accelerating cardiac ﬁbrosis. Among the important
regulators of aging-related processes is miR-34a, with
phosphatase 1 nuclear–targeting subunit (PNUTS),
also known as PPP1R10, as the target. Aging-induced
expression of miR-34a and inhibition of PNUTS is
associated with telomere shortening, deoxyribonu-
cleic acid damage, cardiomyocyte apoptosis, and
impaired functional recovery after ischemic injury
(47). Hence, proﬁbrotic mechanisms involved in AF
pathogenesis are clearly enhanced by aging.Signaling
pathways
(MAPK, ERK,
JNK, p38)
Transcriptional
factors (e.g.,
NF-kB)
Target genes
expression
Fibrotic
remodeling
ase; MAPK ¼ mitogen-activated protein kinase; NADPH ¼ reduced nicotinamide-adenine
; ROS ¼ reactive oxygen species; other abbreviations as in Figure 2.
CENTRAL ILLUS
and Myoﬁbrobla
Proﬁbrotic and A
Dzeshka, M.S. et al. 
Aldo¼ aldosterone;
extracellular matrix;
miR ¼ microribonucl
oxygen species; TGF
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948CARDIOMYOCYTE–CARDIAC
FIBROBLAST COMMUNICATION
Close interaction between cardiomyocytes and car-
diac (myo)ﬁbroblasts is essential for their function.
These interactions are facilitated by multiple para-
crine signals, including those predisposing to ﬁbrosis
(Central Illustration). Cardiomyocytes, cardiac ﬁbro-
blasts, and myoﬁbroblasts share many commonTRATION Cardiomyocytes, Cardiac Fibroblasts,
sts Crosstalk and Paracrine Factors Mediating
ntiﬁbrotic Effects
J Am Coll Cardiol. 2015; 66(8):943–59.
Ang II¼ angiotensin II; CTGF¼ connective tissue growth factor; ECM¼
ET ¼ endothelin; FGF ¼ ﬁbroblast growth factor; IL ¼ interleukin;
eic acid; PDGF ¼ platelet-derived growth factor; ROS ¼ reactive
¼ transforming growth factor; TNF ¼ tumor necrosis factor.molecular pathways (mediated by angiotensin II,
TGF-b1, endothelin, and cytokines). However, the
response to signaling may vary depending on cell
type: hypertrophy and reduced cell survival of car-
diomyocytes are promoted by angiotensin II–induced
release of TGF-b1 and endothelin-1 from ﬁbroblasts,
whereas angiotensin II was also found to trigger
release of TGF-b1 and endothelin-1 from cardio-
myocytes and to stimulate ﬁbroblast proliferation
and differentiation to the myoﬁbroblast phenotype
and synthesis of ECM components (48). Greater
proliferation of ﬁbroblasts was observed around car-
diomyocytes expressing angiotensin II receptor type 1
receptors, compared with cells with the angiotensin II
receptor type 1 gene knocked out (49).
There are also differences between cardiomyocytes
and cardioﬁbroblasts in receptor density and receptor
kinase activity, which may interfere with the ﬁnal
effects of effector molecules. For example, ﬁbroblasts
are known to carry more angiotensin II receptors than
cardiomyocytes (49). Multiple other regulatory sub-
stances are implicated in the interplay between ﬁ-
broblasts and cardiomyocytes (e.g., ﬁbroblast growth
factor 2, interleukins, natriuretic peptides, and miRs)
(48). Some stimuli are attributed predominantly
to ﬁbroblasts (e.g., platelet-derived growth factor
[PDGF], ﬁbroblast growth factor 2, and activation by
mechanical stretching), whereas abnormalities in cal-
cium handling are largely seen in cardiomyocytes (50).
Cardiac remodeling requires ﬁbrosis as an essential
component and is a complex process that also in-
corporates multiple other pathways, such as hypoxia
signaling, the osteoprotegerin/RANK/RANKL axis,
and Ca2þ signaling. A detailed description of these
pathways is beyond the scope of the current review.
In summary, the ECM is a macromolecular, meta-
bolically active, dynamic network of ﬁbers (predom-
inantly collagen) and cells (predominantly cardiac
ﬁbroblasts with a capacity to differentiate into myo-
ﬁbroblasts) that is essential for normal heart function.
Cells surrounding and inﬁltrating the ECM are linked
to the ﬁbrillar component and hence are capable of
responding to mechanical stretch and stress, as well
as to a variety of autocrine and paracrine stimuli by
change in their proliferation, migration, and intensity
of collagen synthesis. These processes may have an
unfavorable role in cardiac remodeling and the
pathogenesis of cardiovascular diseases.
ATRIAL FIBROSIS IN AF
A variety of signaling systems are involved in the
promotion of atrial ﬁbrosis, as evidenced by
numerous human and animal data (Tables 1 and 2).
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structural remodeling, as well as a consequence of
other cardiovascular diseases that result in atrial
overload and stretch. Conditions associated with
atrial ﬁbrosis include hypertension, valvular heart
disease, and HF, which cause broadly similar histo-
logical changes in the atrial myocardium (51). How-
ever, the precise causality between AF and atrial
ﬁbrosis may be difﬁcult to establish.
Experimental data have also yielded controversial
results. For example, some models of atrial tachyar-
rhythmia demonstrated marked biatrial dilation
with changes in atrial architecture and myocyte
characteristics (e.g., loss of myoﬁbrils; accumulation
of glycogen; changes in mitochondrial number,
shape, and size; fragmentation of sarcoplasmic retic-
ulum; dispersion of nuclear chromatin) while the
interstitial space remained unaltered, with no evi-
dence of increased connective tissue content (52). In
contrast, more recent studies of rapid atrial pacing
demonstrated up-regulation of potent proﬁbrotic
factors, such as angiotensin II and TGF-b1 (53), and
increased collagen content in the atrial interstitium
(54). The discrepancy might be attributable to the
time required for development of detectable ﬁbrosis
after initiation of proﬁbrotic pathways. For example,
in a mouse model of HF, there were no signs of his-
tological ﬁbrosis in the left atrium at 8 weeks, despite
increased expression of genes related to ﬁbrosis (55).
This discrepancy may also suggest that despite the
activation of proﬁbrotic genes, other, poorly under-
stood mechanisms of inhibition of ﬁbrosis exist.
Background cardiovascular disease causing HF can
be associated with more advanced atrial changes. For
example, a model produced by a combination of rapid
atrial pacing with mitral regurgitation inevitably
resulted in intercellular space expansion in the left
atrium and AF (56). This observation is consistent
with an HF model of AF caused by ventricular
tachypacing, in which connective tissue contained
increased numbers of ﬁbroblasts, more collagen, and
signs of degeneration and necrosis, compared with an
atrial pacing model (57). Cardin et al. (58) noted that
ventricular tachypacing led to an w10-fold over-
expression of collagen messenger ribonucleic acid in
atrial cardiomyocytes as early as 24 h and progressed
further at 2 weeks, compared with atrial pacing. Of
note, 8 collagen genes were up-regulated >10-fold,
ﬁbrillin was up-regulated 8-fold, and MMP2 was up-
regulated 4.5-fold at 2 weeks; however, there were
no changes in their expression at 24 h. In addition,
TGF-b1 levels in failing hearts in animals appeared to
be higher than in nonfailing hearts (59). Although
development of atrial ﬁbrosis associated with HF hasbeen well documented in several animal models of
AF, cardiac ﬁbrosis is unlikely to be the sole mecha-
nism of HF, including HF with preserved ejection
fraction. For instance, predominant electrical re-
modeling with minimal (if any) evidence of atrial
ﬁbrosis and preservation of ventricular contractility
was seen in a sheep model of prolonged persistent AF
induced by intermittent atrial tachypacing, but there
was no signiﬁcant tachycardia during the observation
period (60). More recently, Martins et al. (61) reported
that long-term AF with duration up to 1 year and
transition to persistent arrhythmia was accompanied
by progressively increasing atrial dilation, mitral
valve regurgitation, myocyte hypertrophy, and at-
rial ﬁbrosis, with no evidence of left ventricular
dysfunction.
Thus, atrial remodeling is the mainstay of AF
initiation and perpetuation. Atrial structural and
functional changes may develop as a result of un-
derlying cardiac conditions, pathological systemic
processes, or AF itself. Atrial remodeling also com-
monly occurs as a part of age-related processes.
However, the relationship between the course of AF
and atrial ﬁbrosis is complex and nonlinear, meaning
that higher levels of collagen deposition within the
atria do not always cause more frequent paroxysms
of the arrhythmia and its progression toward the
persistent or permanent type. A plethora of mecha-
nisms (i.e., hemodynamic alterations, mechanical
stretching, changes in hormones, growth factors, and
proinﬂammatory cytokines) modulates the severity
of atrial ﬁbrosis. A large body of experimental and
clinical data has already provided insights into the
key mechanisms of atrial ﬁbrosis.
EXTRACARDIAC AND GENETIC FACTORS
CONTRIBUTING TO ATRIAL FIBROSIS
Multiple noncardiac factors predispose to ﬁbrosis in
AF, including obesity, metabolic syndrome, use of
toxic substances, athlete’s heart, obstructive sleep
apnea, systemic inﬂammation, and thyrotoxicosis. All
of these factors ultimately affect the myocardium
(62). Recently, diabetes, a disease associated specif-
ically with cardiomyopathy and excessive cardiac
ﬁbrosis, was shown to triple the risk of AF in obese
subjects (63). Obesity leads to electrical and structural
atrial remodeling and is associated with diastolic
ventricular impairment, atrial dilation, and myocar-
dial lipidosis (64). Obesity in AF is related to delay
and signiﬁcant heterogeneity in atrial conduction,
atrial inﬂammatory inﬁltration, and interstitial
ﬁbrosis. Pathways underlying these changes include
activation of TGF-b1 signaling, oxidative stress, and
TABLE 1 Studies on Mechanisms of Atrial Fibrosis in AF in Humans
First Author, Year (Ref. #) n (AF/SR)
Sample
Tested
LVEF, %
(AF/Controls) Results (AF vs. Controls) Observed Associations
Adam et al., 2010 (105) 5/5 LAA 61  6/59  6 [collagen, CTGF, NADPHox, Rac1,
N-cadherin, connexin 43, Ang II
NA
Adam et al., 2012 (106) 5/5 LAA 61  6/59  6 [miR-21 miR-21 with collagen, CTGF, Rac1,
LOX, Ang II
Cao et al., 2013 (107) 48/24 RAA 63  5 (paroxysmal),
64  5 (persistent)/
64  3
[OPG, RANKL, RANK, RANKL/OPG
ratio
(In AF) OPG, RANKL, RANK,
RANKL/OPG ratio with
collagen types I and III
Dawson et al., 2013 (108) 17/30*
17/19
Plasma
RAA
60  2/69  1 YmiR-29b
YmiR-29b in chronic AF
NA
Gramley et al., 2007 (109) 42/104 RAA 48  12 [collagen content, activity
4MMP2, MMP9
(mRNA and protein levels),
YPAI, TIMP1 and 2 (mRNA)
with [ duration of AF
NA
Gramley et al., 2010 (68) 42/116 RAA 50  11/47  12 [collagen content, HIF-1a, HIF-2a,
VEGF, KDR, pKDR, and
microvessel density
NA
Gramley et al., 2010 (110) 61/102 RAA 48  11 [collagen content, early [ and
later Y responsiveness to TGF-b1
with [ duration of AF: initially
[TGF-b1 (mRNA and protein),
TbRII, phSmad2, Smad4 (protein)
followed by a YTbRI phSmad2
(protein) and [Smad7 (protein)
NA
Kallergis et al., 2008 (111) 70/20 Serum 60  4 (paroxysmal),
56  9 (persistent)/
60  5
[CITP, CICP, TIMP1 NA
Ko et al., 2011 (112) 10/10 RAA 53  15/44  17 [collagen content, CTGF (protein
and mRNA)
NA
Li et al., 2013 (113) 28/12 RA NA [collagen content, TGF-b1, Smad3,
and CTGF
TGF-b1, CTGF (mRNA and protein)
with collagen content,
TGF-b1, CTGF
Mayyas et al., 2010 (114) 32/21 LAA 51  2/53  3 [ET-1
4ETAR or ETBR
ET-1 with LA size, AF persistence
Nishi et al., 2013 (115) 16/13 RA 70  8
(unsuccessful Maze),
53 15 (successful Maze)/
62.0 9
[miR-21, miR-23b, miR-199b,
miR-208b
miR-21 with collagen content
Okumura et al., 2011 (116) 50/0 Serum NA YhsCRP, IL-6, ANP, BNP
[MMP2, TIMP2, CITP during follow-up
MMP2 with AF recurrence
Polyakova et al., 2008 (117) 24/24 RA, RAA 46  10/46  13 [collagen content, MMP2, MMP9,
TIMP1, TIMP2, RECK, TGF-b1,
Smad2 and phSmad2
NA
Qu et al., 2009 (118) 20/20 RA 51  15/63  14.63 [collagen content, TNFa, IL-6 and
NFkB activity
NFkB activity with TNFa, IL-6, and
collagen content
Rahmutula et al., 2013 (59) 17/NA RA NA [TGb1 and TGF-b1 signaling–related
proteins (e.g., phSmad2,
Smad6, Ang II)
NA
Richter et al., 2011 (119) 30/0 Serum 62  2 [MMP9, TGF-b1, PIIINP after ablation PIIINP with AF recurrence;
MMP9, TGF-b1 with ablation-
induced LA volume reduction;
MMP9 with RF energy on
ablation
Rudolph et al., 2010 (120) 34/35 Plasma, RAA 49  89/52  9 [MPO NA
Swartz et al., 2012 (121) 18/36 LAA, RAA,
serum
49  12/51  8 [collagen content, collagen type I,
III, TGF-b1, Ang II (mRNA)
[PICP, PIIINP
Collagen content with PICP
Wang et al., 2015 (122) 30/17 LAA 63  7/70  4 [miR-146b-5p, MMP9, collagen
content; YTIMP4
miR-146b-5p with TIMP4 and
collagen content
Wilhelm et al., 2006 (123) 30/20 RAA NA 4collagen content NA
Wu et al., 2013 (124) 200/0 Plasma 53  10/57  6† NA TGF-b1 with AF recurrence
Continued on the next page
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TABLE 1 Continued
First Author, Year (Ref. #) n (AF/SR)
Sample
Tested
LVEF, %
(AF/Controls) Results (AF vs. Controls) Observed Associations
Xi et al., 2013 (125) 83/52† RAA 62  6/30  5 4RANK, RANKL RANK, RANKL, RANKL/OPG ratio
with collagen content
Xie et al., 2013 (126) 22/15 LA 55/60 [ﬁbrocytes, collagen I
and alpha-SMA
Fibrocytes with collagen content, LA
volume index
Xu et al., 2009 (127) 27/18 LA, RA 54  9/59  12 [collagen type I, MMP1 and
MMP9 (mRNA)
YTIMP1 (mRNA)
Collagen type I (mRNA) with
atrial diameter;
MMP1, MMP9 (mRNA) with
TIMP1 (mRNA)
*Recurrent AF/nonrecurrent AF. †Chronic AF/AF with subsequent SR recovery.
[ ¼ increased; Y ¼ reduced;4 ¼ not changed; AF ¼ atrial ﬁbrillation; Ang ¼ angiotensin; ANP ¼ atrial natriuretic peptide; BNP ¼ B-type natriuretic peptide; CICP ¼ collagen type I C-terminal propeptide;
CITP ¼ collagen type I C-terminal telopeptide; COL1A1 ¼ gene encoding alpha-1 type I collagen; COL3A1 ¼ gene encoding alpha-1 type III collagen; CTGF ¼ connective tissue growth factor; ET ¼ endothelin;
ETAR ¼ type A endothelin-1 receptor; ETBR ¼ type B endothelin-1 receptor; HIF ¼ hypoxia-inducible factor; hsCRP ¼ high-sensitivity C-reactive protein; IL ¼ interleukin; KDR ¼ vascular endothelial growth
factor receptor 2; LA ¼ left atrium; LAA ¼ left atrial appendage; LOX ¼ lysyl oxidase; LVEF ¼ left ventricular ejection fraction; miR ¼ microribonucleic acid; MMP ¼ matrix metalloproteinase; MPO ¼
myeloperoxidase; mRNA ¼ messenger ribonucleic acid; NA ¼ not available; NADPHox ¼ nicotinamide adenine dinucleotide phosphate oxidase; NFkB ¼ nuclear factor kappa B; OPG ¼ osteoprotegerin; PAI ¼
plasminogen activation inhibitor; phSmad ¼ phosphorylated Smad; PICP ¼ procollagen type I C-terminal propeptide; PIIINP ¼ procollagen type III N-terminal propeptide; pKDR ¼ phosphorylated KDR; RA ¼
right atrium; RAA ¼ right atrial appendage; Rac1 ¼ Ras-related C3 botulinum toxin substrate 1; RANK ¼ receptor activator of nuclear factor kappa B; RANKL ¼ receptor activator of nuclear factor kappa B
ligand; RECK ¼ reversion-inducing cysteine-rich protein with Kazal motifs; SMA ¼ smooth muscle actin; Smad ¼ a transcription factor, named by fusion of the Caenorhabditis elegans Sma and Drosophila Mad
(mothers against decapentaplegic) proteins, in reference to its homology to these proteins; SR ¼ sinus rhythm; TbRI ¼ type I transforming growth factor beta-1 receptor; TbRII ¼ type II transforming growth
factor beta-1 receptor; TGF-b1 ¼ transforming growth factor beta-1; TIMP ¼ tissue inhibitor of matrix metalloproteinase; TNF ¼ tumor necrosis factor; VEGF ¼ vascular endothelial growth factor.
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951up-regulation of PDGF and endothelin (65). The
pericardial fat envelope could produce a constrictive
effect, thus disturbing cardiac relaxation. Some adi-
pokines clearly have proﬁbrotic properties (e.g.,
activin A, a member of the TGF-b1 superfamily),
whereas AF itself affects adipocyte-related gene
expression, facilitating expansion of cardiac fat (66).
Obstructive and central sleep apnea are also asso-
ciated with atrial remodeling and AF (67). Animal
models of obstructive sleep apnea showed substantial
connexin 43 down-regulation and altered expression
of channel proteins, with net effects of shortening the
atrial refractory period, slowing atrial conduction,
cardiomyocyte apoptosis, and cardiac ﬁbrosis.
Repeated apnea episodes associated with chronic
hypoxia trigger production of strongly proﬁbrotic
hypoxia-inducible factors 1a and 2a (68). Moreover,
such patients have increased angiotensin-converting
enzyme and interleukin-6 expression, with inhibited
degradation of atrial collagen via MMP2 (69). In
addition, sleep apnea leads to myocardial hypertro-
phy and diastolic dysfunction, thus further potenti-
ating development of HF in the presence of AF
(70,71). Multiple other factors contribute to atrial
remodeling and chronic low-grade inﬂammation with
increased propensity to AF (e.g., chronic kidney dis-
ease, diabetes) (11).
AF has a genetic predisposition. The genetic back-
ground of AF is complex, involving multiple path-
ways. In “lone” AF (i.e., in the absence of apparent
cardiovascular disease), histological and imaging ev-
idence suggests a similar extent of atrial ﬁbrosis as in
AF patients with structural heart disease (72). A spe-
ciﬁc ﬁbrotic atrial cardiomyopathy has been sug-
gested as an underlying condition predisposing toAF development and persistence, and it is likely to
have a genetic background (73,74). One of the genes
involved in atrial development is PITX2. Deﬁciency of
this gene results in formation of enlarged atria with
thin walls and prominent deﬁciency in ion channel
expression (75). AF is also related to polymorphisms
in genes involved in ﬁbrotic pathways, such as those
responsible for modulation of the synthesis of
interleukin-1 and -6 (2). Nonetheless, there is pres-
ently a lack of robust evidence of target genes directly
responsible for AF-related cardiac ﬁbrosis, and
further research is warranted.
VENTRICULAR FIBROSIS IN AF
Association of AF with ventricular ﬁbrosis is less
established than for atrial ﬁbrosis. Ventricular ﬁbrotic
changes are more pronounced in AF patients than in
subjects with sinus rhythm, both with magnetic
resonance or ultrasound imaging (76,77). In addition,
more extensive changes were found in patients with
permanent or persistent arrhythmia compared with
those with paroxysmal AF (76–78). These reports were
conﬁrmed by use of animal data implicating ventric-
ular ﬁbrosis in cardiac remodeling and rate control in
AF (79). Avitall et al. (80) observed more extensive
ventricular ﬁbrosis in AF when ventricles were not
protected from a high atrial rate with atrioventricular
node ablation than in ablated animals.
Atrial and ventricular ﬁbrosis in AF is likely to
share many common mechanisms, although the
extent may vary between the 2 parts of the heart. In
transgenic mice with TGF-b1 overexpression, TGF-b1
up-regulation was more pronounced in atria than in
ventricles. High TGF-b1 levels were associated with
TABLE 2 Studies on Mechanisms of Atrial Fibrosis in AF in Animal Experiments
First Author, Year (Ref. #)
n
(Experiment/Control) Samples Tested Model Results (Experiment Vs. Controls)
Abed et al., 2013 (65) 30 LA, LAA, RA,
and RAA
High-calorie diet [AF inducibility, LA volume, collagen content,
inﬂammatory inﬁltrates, lipidosis, ET-1, ETAR,
ETBR, TGF-b1, PDGF with [ adiposity
Adam et al., 2012 (106) NA LA Tx, Rac1 overexpression [collagen content, miR-21, spontaneous AF
Cardin et al., 2012 (128) NA Myocardium Coronary artery ligation [miR-21, LA dilation and collagen content, AF inducibility
Dawson et al., 2013 (108) 57/37 LA Ventricular tachypacing;
Tx, miR-29b knockout
YmiR-29b, miR-133a, miR-133b;
[collagen content
[collagen content, COL1A1 (mRNA)
He et al., 2011 (53) 8/8 LA Atrial tachypacing [Ang II, TGF-b1, phSmad2/3, Arkadia, hydroxyproline
expression;
YSmad7 expression
Ko et al., 2011 (112) 6/6 LA, RA Atrial tachypacing [Ang II, CTGF (protein and mRNA)
Li et al., 2012 (54) 21/21 LA Atrial tachypacing [collagen content, chronic inﬂammation;
YmiR-133 and miR-30
Rahmutula et al., 2013 (59) 15/15 Myocardium Tx, TGF-b1 overexpression [LA ﬁbrosis, AF inducibility, TGF-b1 signaling–related
genes in atria (TIMP, MMP, collagen, Smad2 or 3, TbRI and II)
Rudolph et al., 2010 (120) NA LA MPO knockout, angiotensin
II pre-treatment
Ycollagen content, MPO, MMP2, MMP9, and AF susceptibility
Saba et al., 2005 (129) 32/37 Myocardium Tx, TNF alpha overexpression [collagen content, AF inducibility
Verheule et al., 2004 (130) 30/30 Myocardium Tx, TGF-b1 overexpression [LA ﬁbrosis, AF inducibility
PDGF ¼ platelet-derived growth factor; Tx ¼ transgenic; other abbreviations as in Table 1.
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952enhanced expression of only 2 proﬁbrotic genes in
ventricles but of 80 genes in atria. Interestingly, TbRI,
TbRII, and Smad protein levels were similar in ven-
tricles and atria, but Smad2 phosphorylation was
increased only in atria, making them prone to devel-
opment of selective ﬁbrosis (59). Several mechanisms
have been suggested for the different effects ofTABLE 3 Suggested Mechanisms of Predisposition of
Atrial Versus Ventricular Myocardium to Fibrosis
Gene expression
Higher expression of genes encoding extracellular matrix (e.g.,
ﬁbronectin, laminin, ﬁbulin), cell signaling (PDGF, PDGF
receptor, angiopoietin, VEGF), in ﬁbroblasts
Signaling pathways
Greater signaling via canonical TGF-b1 pathway including enhanced
receptor binding, receptor-kinase activity, Smad2/3
phosphorylation, reduced expression of the inhibitory Smad7 in
atrial myocytes with further stimulation of atrial ﬁbroblasts
Higher level of endogenous AT1 receptor and greater enhancement
of receptor level following pathological inﬂuences
Differential expression of adapter/scaffolding proteins (b-arrestin-1,
G-proteins) involved in the AT1 receptor–dependent aldosterone
synthesis and secretion
Higher expression of PAI-1
Cellular proliferation
Higher myoﬁbroblast density in healthy and diseased hearts with
faster cell surface area being increased, distinct morphology at
conﬂuence, and greater alpha-SMA and vimentin expression
Higher proportion of ﬁbroblasts in mitotic phases and displaying
enhanced gene expression of ﬁbroblast-selective markers
Greater proliferation response of atrial ﬁbroblasts for a range of
growth factors (e.g., PDGF, angiotensin II, ET-1, TGF-b1)
AT1 ¼ angiotensin II receptor type 1; PAI ¼ plasminogen activator inhibitor; other
abbreviations as in Tables 1 and 2.TGF-b1 in ventricles versus atria (Table 3). Impor-
tantly, the processes described earlier were reported
in intact ventricles. When TGF-b1 overexpression was
combined with other pathophysiological stimuli (e.g.,
those seen in HF), TGF-b1–mediated proﬁbrotic ven-
tricular effects appeared to be enhanced, although
atrial ﬁbrosis still predominated. In addition, atrial
ﬁbroblasts are more susceptible to PDGF, angiotensin
II, and endothelin-1, indicating that their activity
is pre-modulated by local atrial factors (81). Hemo-
dynamic changes (e.g., stretch) have a differential
effect, and the precise biochemical processes acting
on ﬁbroblast activity in ventricles and atria remain
unclear at present.
In summary, the cardiac proﬁbrotic microenviron-
ment in AF is unlikely to be strictly limited to the
atria, and the ventricular myocardium is also likely to
be affected. Even within the atrial myocardium,
ﬁbrotic changes take years to become detectable with
the diagnostic methods currently available. With the
considerably higher myocardial thickness of the
ventricles, detectable ventricular ﬁbrosis may require
a prolonged time to develop unless ampliﬁed by
coexisting pathological conditions, such as hyper-
tension, coronary artery disease, and HF.
IMAGING OF CARDIAC FIBROSIS
Signiﬁcant technological advances allow more possi-
bilities for characterization and quantiﬁcation of focal
and diffuse cardiac ﬁbrosis, which was only possible
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953with biopsy in the past. The most commonly used late
(delayed) gadolinium enhancement cardiac magnetic
resonance (DE-CMR) imaging relies on the different
abilities of healthy myocardium and areas of ﬁbrotic
tissue to clear gadolinium, an agent that shortens T1
relaxation time. Fibrotic tissue is characterized by
slowing of gadolinium washout, resulting in greater
signal compared with surrounding “reference” tissue.
However, ﬁnding appropriate reference tissue for
quantiﬁcation of diffuse cardiac ﬁbrosis poses a
problem (82,83).
Another cardiac magnetic resonance (CMR)–based
method, T1 mapping, was developed to overcome
this problem. T1 mapping is a calculation of a post-
contrast myocardial T1 time by imaging a given
plane with sequentially increasing inversion times;
there is no need to compare the results versus normal
reference tissue before or after use of a contrast
agent. This method allows demonstration of diffuse
ﬁbrotic ﬁbers that might appear nearly isointense by
using delayed enhancement (82,83).
Despite being the gold standard, CMR is not widely
available. Hence, echocardiography remains an
alternative for evaluation of cardiac ﬁbrosis on the
basis of the dependency of acoustic properties on
myocardial composition. Collagen causes ultrasound
scattering and attenuation, which can be measured as
integrated backscatter (84). Furthermore, with echo-
cardiography, functional assessment as strain peak
and strain velocity (parameters that characterize
reservoir performance) was found to predict the
degree of ﬁbrosis detected in histological specimens
and via CMR (85,86).
CLINICAL IMPLICATIONS AND PROGNOSTIC
EFFECTS OF ATRIAL FIBROSIS
Atrial remodeling, including excessive ﬁbrosis, has
major clinical implications in AF. Numerous studies
link more extensive atrial interstitial ﬁbrosis to lower
effectiveness of AF catheter ablation and the Maze
procedure, increased risk of development of post-
operative AF, and impaired post-procedural recovery
of atrial function (Table 4). Interestingly, delayed
enhancement of the atrial myocardium is helpful for
evaluation of post-ablation atrial ﬁbrosis and its
relation to left atrial reverse remodeling on sinus
rhythm (87). Patients undergoing pulmonary vein
isolation had a higher AF recurrence rate, with a
lesser degree of left atrial and pulmonary vein scar-
ring on DE-CMR (88).
There are limited data on the association of atrial
ﬁbrosis with stroke risk in AF patients. An association
was found between the percentage of atrial ﬁbrosisassessed via DE-CMR and a higher CHADS2 (conges-
tive heart failure, hypertension, age $75 years, dia-
betes mellitus, and stroke/transient ischemic attack)
score and stroke history (89). Moreover, in this pop-
ulation (n ¼ 387, 36 strokes), adding left atrial
ﬁbrosis to the risk model (i.e., CHADS2 but not ac-
counting for previous stroke due to the retrospective
nature of the study) improved the C-statistic from
0.58 to 0.72. This outcome was consistent with
another study that demonstrated better prediction of
left atrial thrombosis or spontaneous echocardio-
graphic contrast by addition of the degree of atrial
ﬁbrosis to either the CHADS2 or CHA2DS2-VASc
(congestive heart failure, hypertension, age $75
years, diabetes mellitus, stroke/transient ischemic
attack, vascular disease, age 65 to 74 years, sex
category) scores (90). However, routine use of ex-
pensive, and not universally available, DE-CMR for
stroke prediction is not practical at present compared
with available and recommended stroke risk ass-
essment tools; the approach clearly needs further
validation.
Galectin-3 is involved in regulation of ﬁbrosis and
was found to be associated with left atrial volume
index and AF (odds ratio: 87.5 [95% conﬁdence in-
terval: 6.1 to 1,265.0]). It was also signiﬁcantly higher
in patients with persistent AF than in those with the
paroxysmal type of arrhythmia (91).
CLINICAL IMPLICATIONS AND PROGNOSTIC
EFFECT OF VENTRICULAR FIBROSIS
Ventricular ﬁbrosis has a detrimental effect on both
systolic function (due to replacement of apoptotic
and necrotized myocardium) and diastolic function
(due to increasing stiffness and decreasing compli-
ance) (14). This makes ventricular ﬁbrosis relevant in
the context of HF with both preserved and reduced
ejection fraction.
Although scarce data are available on the histo-
logical assessment of ventricular myocardial ﬁbrosis
in patients with AF, a small case series of ventricular
biopsy specimens suggests the presence of active
myocarditis or nonspeciﬁc necrotic/ﬁbrotic changes
in patients with lone AF (92). It is probable that most
lone AF cases have background myocardial pathology
that cannot easily be determined with the use of
routine tests and reﬂect primary electrical distur-
bances and subclinical cardiomyopathies, likely
associated with myocardial ﬁbrosis.
Contemporary markers of ventricular ﬁbrosis
(e.g., beta-galactoside–binding lectin galectin-3) are
increasingly being studied in patients with HF and
have predictive value for adverse outcomes. Their
TABLE 4 Studies on the Prognostic Signiﬁcance of Atrial Fibrosis in AF Patients
First Author, Year (Ref. #) n Duration of Follow-Up
Evaluation of
Atrial Fibrosis Intervention Study Outcome
Association of Atrial Fibrosis and Study
Outcome, OR or HR (95% CI)
Akoum et al., 2011 (131) 144 283  167 days DE-MRI AF catheter ablation AF recurrence Increasing recurrence rate with increasing
ﬁbrosis degree
Canpolat et al., 2015 (132) 41 18 months DE-MRI, TGF-b1 AF catheter ablation AF recurrence 1.127
den Uijl et al., 2011 (133) 170 12  3 months IBS AF catheter ablation AF recurrence 2.80 (2.17–3.61)
Ho et al., 2014 (134) 3,306 10 yrs Galectin-3 NA Incident AF 1.19 (1.05-1.36)*
Kornej et al., 2015 (135) 119 6 months Galectin-3 AF catheter ablation AF recurrence Higher in AF patients but did not predict AF
recurrence
Kubota et al., 2012 (136) 27 3 yrs IBS None Progression from
paroxysmal to
persistent AF
HR: 8.74 for patients with IBS $20 dB vs. <20 dB
Kuppahally et al., 2010 (137) 68 1 yr DE-MRI AF catheter ablation AF recurrence 1.04 (1.01–1.08)
Ling et al., 2014 (138) 132 1, 3, 6, 12, 18,
24, 30 months
T1 mapping AF catheter ablation AF recurrence 38% of AF recurrence in patients with T1
time <230 ms vs. 25% in patients
with T1 time >230 ms
Malcolme-Lawes et al., 2013 (139) 50 1 yr DE-MRI AF catheter ablation AF recurrence Increasing recurrence rate with increasing
ﬁbrosis degree
Marrouche et al., 2014 (140) 272 475 days DE-MRI AF catheter ablation AF recurrence 1.06 (1.03–1.08)
McGann et al., 2014 (141) 386 1 yr DE-MRI AF catheter ablation AF recurrence 4.89
Oakes et al., 2009 (142) 81 9.6  3.7 months DE-MRI AF catheter ablation AF recurrence 4.88 (1.73–13.74)
Olasinska-Wisniewska et al. 2012 (143) 66 12 months Histology AF catheter ablation,
mitral valve surgery
AF recurrence 1.09 (1.012–1.17)
Park et al., 2013 (144) 128 1 yr TGF-b1 Maze procedure Absence of atrial
mechanical contraction
7.47 (1.63–34.4)
Rienstra et al., 2014 (145) 3,217 10 yrs Soluble ST2 NA Incident AF No association
Rosenberg et al., 2014 (146) 2,935 8.8 yrs PIIINP NA Incident AF 0.85 (0.72–1.00) and 0.93 (0.88–0.99) at the
10th and 25th percentiles, setting the median
as the reference, no association at the 75th
and 90th percentiles
Sasaki et al., 2014 (77) 113 13.8 (8.7–19.9)
months
IBS AF catheter ablation AF recurrence 1.04 (1.01–1.07)
Seitz et al., 2011 (147) 22 NA DE-MRI AF catheter ablation “Difﬁculty” of AF ablation
(time to terminate AF;
radiofrequency duration
until AF termination; complex
fractionated atrial electrogram
area/LA surface)
Signiﬁcant correlation between the ﬁbrosis grade
and the electrophysiological substrate indexes
Wang et al., 2009 (148) 74 NA IBS CABG Post-operative AF Higher IBS in post-operative AF vs. SR
Wu et al., 2013 (124) 200 10.9  7.4 months TGF-b1 AF catheter ablation AF recurrence 1.11 (1.01–1.22)
*Signiﬁcant association in univariate analysis only, not signiﬁcant after adjustment for traditional clinical AF risk factors.
CABG ¼ coronary artery bypass graft; CI ¼ conﬁdence interval; DE-MRI ¼ delayed enhancement magnetic resonance imaging; HR ¼ hazard ratio; IBS ¼ integrated backscatter; OR ¼ odds ratio; other abbreviations as in Table 1.
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955speciﬁc relevance in the context of AF remains to be
established (93,94).
Collagen turnover markers of prognostic signiﬁ-
cance were assessed in hypertensive heart disease,
hypertrophic cardiomyopathy, and HF (95,96). How-
ever, the major limitation of blood markers of
collagen turnover is that they are not cardiac-speciﬁc
and may not accurately reﬂect myocardial collagen
content. Hence, the results are often conﬂicting,
depending largely on the selection of study cohorts
(e.g., exclusion of patients with hepatic and kidney
dysfunction, pulmonary ﬁbrosis, osteoporosis, and
metastatic bone disease, among others, or measuring
the cardiac gradient of collagen markers [i.e., blood
from coronary sinus vs. systemic circulation]) (97).
It is even more problematic or even impossible to
distinguish between the atrial and ventricular con-
tributions to circulating levels of byproducts of
collagen synthesis and degradation. Consequently,
attribution of elevated markers of collagen turnover
to AF-related atrial ﬁbrosis alone might not be
entirely correct.
For example, in the I-PRESERVE (Irbesartan in
Heart Failure With Preserved Systolic Function)
collagen substudy that included 29% AF patients,
procollagen type I amino-terminal peptide and pro-
collagen type III amino-terminal peptide were pre-
dictive of all-cause mortality and cardiovascular
hospitalizations (98). This association lost signiﬁcance
after adjustment for other confounders, however.
Similarly, the majority of imaging-based studies on
the evaluation of ventricular ﬁbrosis focused on pa-
tients with arterial hypertension, dilated and hyper-
trophic cardiomyopathy, and HF; only a few directly
addressed patients with AF. Moreover, those few
studies with AF included mostly patients referred for
AF ablation, which is currently indicated for patients
with paroxysmal or persistent arrhythmia resistant to
antiarrhythmic treatment. Thus, these studies may
not be representative of the AF population overall.
Recently, Neilan et al. (99) found an association
between the presence (hazard ratio: 5.08 [95% conﬁ-
dence interval: 3.08 to 8.36]) and extent (hazard
ratio: 1.15 [95% conﬁdence interval: 1.10 to 1.21]) of
left ventricular late gadolinium enhancement on
magnetic resonance imaging and all-cause mortality
(n ¼ 664, median follow-up 42 months, mean left
ventricular ejection fraction 56  10%). The observed
associations were even stronger when patients with
evidence of ischemic heart disease were excluded
from analysis. The major limitation of this study was
the inclusion of patients selected for AF ablation
with a median duration of arrhythmia since onset of
50 days.Another study that involved patients with arterial
hypertension and longer AF duration (median 37
months) using CMR T1 mapping found the left ven-
tricular extracellular volume to be independently
predictive of AF recurrence, as well as of the com-
posite endpoint of AF recurrence admission with HF,
and death (hazard ratio: 1.35 [95% conﬁdence inter-
val: 1.21 to 1.51]) (100). The prognostic value of diffuse
ventricular ﬁbrosis for AF recurrence after an ablation
procedure was further conﬁrmed by McLellan et al.
(101). They found that a cutoff level of post-contrast
ventricular T1 time <380 ms was associated with
better outcome. In a small cohort of patients without
left ventricular ﬁbrosis, as evidenced by the absence
of late gadolinium enhancement on CMR in patients
with systolic HF, signiﬁcant improvement of left
ventricular function was observed after AF catheter
ablation. However, the study had no comparator
group with established ventricular ﬁbrosis to assess
the effect of sinus rhythm restoration (102).
Thus far, similar to atrial ﬁbrosis, it is unclear
whether AF triggers proﬁbrotic pathways in the left
ventricle, is merely a marker of pre-existing ﬁbrotic
changes, or both.
TREATMENT APPROACHES TO
REDUCE CARDIAC FIBROSIS
Angiotensin II is a potent stimulator of proﬁbrotic
pathways, angiotensin-converting enzyme inhibitors,
angiotensin receptor antagonists, and mineralocorti-
coid receptor antagonists deemed to reduce ﬁbrosis
progression. This was supported by several animal
studies but not, thus far, by clinical trials. Retro-
spective analyses and meta-analyses of randomized
trials produced inconclusive results, both for the
primary and secondary prevention of AF. It has also
been accepted that overall primary prevention of AF
with these agents is more feasible than secondary
prevention (myocardial ﬁbrosis is more likely to be
slowed down than reversed) (103).
Therefore, inhibitors of the angiotensin axis are
only recommended for AF management when the
arrhythmia is associated with other underlying con-
ditions that are themselves associated with myocar-
dial ﬁbrotic remodeling, such as arterial hypertension
with left ventricular hypertrophy and systolic HF, and
are not recommended in patients with no apparent
cardiovascular disease (e.g., lone AF) (104).
Many other components of proﬁbrotic cardiac
pathways (e.g., TGF-b1, PDGF) represent attractive
therapeutic targets. Their suppression with either
antibody blockade or oligonucleotide interference
reduced interstitial ﬁbrosis in animal experiments.
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956Nonetheless, experience from the animal data must
be conﬁrmed by clinical trials, and a better under-
standing of the details of ﬁbrotic pathways is
required (15).
CONCLUSIONS
AF is associated with ﬁbrotic processes both in atria
and ventricles. Despite common proﬁbrotic path-
ways, signaling seems to differ in the ventricular and
supraventricular parts of the heart. Atrial ﬁbrosis may
precede development of AF, which in turn results in
further progression of atrial remodeling. Structural
heart disease appears to have a greater effect on bothatrial and ventricular ﬁbrosis than arrhythmia per se,
but it allows persistent activation of proﬁbrotic
stimuli. Although the role of atrial ﬁbrosis in AF is
well documented, the implication of ventricular
ﬁbrosis in pathogenesis and the outcomes of condi-
tions associated with AF clearly require further
research.
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